HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
Rhea-AI Summary
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), has announced potential acquisition and financing agreements for $30 million in currently-operating interventional psychiatry clinics. Key points include:
1. A $30 million Term Sheet from a qualified lender for non-dilutive financing, expected to close within 60 days.
2. A non-binding Term Sheet with initial clinic partners generating over $10 million in annual revenue.
3. Projected annualized revenues of $100 million through continued acquisitions by mid-2025.
4. Focus on treating suicidal depression, treatment-resistant depression (TRD), and PTSD using ketamine therapy, TMS, and digital therapeutics.
5. Planned operations in the United States, France, and the United Kingdom.
Positive
- $30 million non-dilutive financing Term Sheet for clinic acquisitions
- Non-binding Term Sheet with initial clinic partners generating over $10 million in annual revenue
- Projected annualized revenues of $100 million through acquisitions by mid-2025
- Expansion into multiple countries: US, France, and UK
- Diversified treatment approach combining pharmaceutical therapy, FDA-approved technologies, and digital therapeutics
Negative
- Term Sheets are non-binding, indicating potential uncertainty in deal completion
- Rapid expansion through acquisitions may pose integration challenges
- Dependence on successful execution of acquisition strategy for revenue growth
News Market Reaction
On the day this news was published, NRXP declined 9.13%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
$30 million - Executed Non-Binding Term Sheet with initial clinic partners generating annual revenue of over
$10 million - Company projects annualized revenues of
$100 million - Additional information to be presented at upcoming HC Wainwright Annual Global Investment Conference in
New York , September 9-11, 2024
The non-dilutive acquisition funding announced today is in addition to the over
Ketamine is increasingly used to treat suicidal depression, treatment resistant depression (TRD) and Post Traumatic Stress Disorder (PTSD). Until now there has been no unified entity organized around delivering consistent outpatient care for suicidal depression, TRD and PTSD that combines pharmaceutical therapy, FDA approved and proven medical technologies such as Transcranial Magnetic Stimulation (TMS), digital therapeutics and access to clinical trial protocols for the newest potential treatments, delivered by properly licensed medical professionals to optimize care of people with these conditions. Collectively, these conditions represent a crisis that results in the death of someone around the globe every minute. HOPE aims to bring a unified, patient-centric and science-based approach to the care of patients and their families.
"HOPE is dedicated to providing an accessible platform to help caregivers address the critical needs of those suffering from suicidal thoughts, TRD, PTSD and related challenges. We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care and demonstrate best-practices for mental health professionals around the world," said Jonathan Javitt and Matthew Duffy, Co-CEOs of HOPE Therapeutics. "These clinics, and others under review, are planned to provide the foundation for a network generating revenue of approximately
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-potential-acquisition-and-financing-agreements-for-30-million-in-currently-operating-interventional-psychiatry-clinics-302230157.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the value of the financing agreement announced by HOPE Therapeutics (NRXP) for clinic acquisitions?
What are the projected revenues for HOPE Therapeutics (NRXP) by mid-2025?
Which countries does HOPE Therapeutics (NRXP) plan to operate in?
What medical conditions does HOPE Therapeutics (NRXP) focus on treating?
What treatment methods does HOPE Therapeutics (NRXP) plan to use in its clinics?
